A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ ) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Ovarian Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female
  • Other Inclusion Criteria:
    1) Subjects with Histologically confirmed epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer. 2) Patients with selected tumor types that have relapsed or progressed after 2 lines of therapy or who are ineligible for other standard of care (SOC) therapies. 3)Histologically or cytologically confirmed metastatic or non-resectable advanced metastatic gastric or gastroesophageal adenocarcinoma.

You may not be eligible for this study if the following are true:

  • 1) Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor for ovarian cancer patients 2) Disease progression within 6 months of starting anti-PD-1 and anti-PD-L1 inhibitors. 3) Active autoimmune disease requiring systemic treatment within the past 12 months. 4) For ovarian cancer: a. Patients who progressed during or within 3 months of first line of platinum-based therapy b. Patients with histologically non-epithelial tumors or ovarian tumors with low malignant potential (i.e., borderline tumors) or mucinous tumors c. Patients with evidence of bowel obstruction requiring hospitalization and decompression within the past 30 days


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.